|
2.6 Etiologie - Environnement
|
|
|
'Everyday chemicals' linked to cancer [NHS Choices]
|
|
|
|
|
|
This
study alone can't inform on a safe or toxic exposure level, either for
people with or for people without BRCA2 mutations. We also can't
conclude that aldehydes provide the whole answer as to why people with
BRCA2 mutations are susceptible to cancer.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
6. Lutte contre les cancers
|
|
|
Big returns on small cancer research investment, study suggests [Reuters]
|
|
|
|
|
|
A
government-backed research collaboration program started in the 1950s
has added about 3.34 million years of life for cancer patients in the
U.S. at an estimated cost of just $125 for each year of life gained
based on successful new treatment options developed through the program,
a new study estimates.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.4 Médico-éco
|
|
|
The Specialists’ Stranglehold on Medicine [NY Times]
|
|
|
|
|
|
Most
Americans mistakenly believe that they must see specialists for almost
every medical problem. What people don’t know is that specialists
essentially determine the services that are covered by insurance, and
the prices that may be charged for them.
|
|
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
Data sharing statements for clinical trials [BMJ]
|
|
|
|
|
|
It
is encouraging that data sharing is already occurring in some settings.
Over the past year, however, we have learnt that the challenges are
substantial and the requisite mechanisms are not in place to mandate
universal data sharing at this time.
|
|
|
|
|
|